# LISCure Biosciences Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liscure-biosciences-co

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.liscure.bio/
- Total disclosed funding: $30M
- Latest round: Series C (Nov 14, 2022)
- Investors on record: 16

## About

LISCure Biosciences Co., Ltd. is a South Korea-based biopharmaceutical company focused on developing innovative therapeutics, specializing in injectable bacteria-mediated cancer immunotherapy and oral microbiome therapeutics.Founded in 2018 in Seongnam, South Korea, LISCure Biosciences Co., Ltd. develops therapeutics targeting various medical conditions. The company was established by HS Chin, who has a history of founding successful ventures. LISCure has secured a total of 6 deals, with its most recent deal on January 10, 2025, raising KRW 20 billion in PRE-IPO funding, bringing the total amount raised to KRW 20 billion.LISCure Biosciences specializes in developing innovative therapeutics through its core offerings of injectable bacteria-mediated cancer immunotherapy and oral microbiome therapeutics. The company operates on its proprietary LMT (LISCure Microbiology-based Technology) platform, which is integral for discovering and analyzing microorganism-based drug candidates. Targeting significant unmet medical needs, LISCure's product pipeline includes therapies aimed at conditions such as non-alcoholic steatohepatitis (NASH), cholestatic liver disease, autoimmune diseases, and various solid tumors, with advancements in microbiome therapeutics for neurological conditions like Parkinson’s and Alzheimer’s diseases. The geographic markets for these products include the United States, Europe, and various regions in Asia, where the company collaborates with prominent research institutions, such as the Mayo Clinic and Scripps Research, to conduct global clinical trials and facilitate joint research initiatives.LISCure Biosciences generates revenue primarily through partnerships and collaborations with research institutions and through the eventual commercialization of its therapeutics. The company’s revenue model is structured around B2B transactions with healthcare providers, research organizations, and pharmaceutical companies, focusing on the development and licensing of its drug candidates, particularly those that attain regulatory approvals. As LISCure progresses its pipeline, particularly with products like LB-P8 for treating primary sclerosing cholangitis, the financial implications of its collaborations will be pivotal for driving future revenue growth.In January 2025, LISCure Biosciences Co., Ltd. raised KRW 20 billion in PRE-IPO funding from various investors to support the development of new medicines, launch its liver disease treatment, and accelerate the commercialization of Exo-Pass N and US trials for the anticancer drug LB-P2D. The company plans to expand its therapeutic offerings and enter new markets, focusing on regions including North America and Europe, to broaden its impact in the biopharmaceutical sector.

## Funding rounds

- Series C, Nov 14, 2022, $5.3M — Hana Securities, CKD Bio
- Series B, Feb 9, 2021, $21M — Korea Investment & Securities, Industrial Bank of Korea, KDB Capital, LabGenomics. Co., Ltd., EuBiologics Co. Ltd., Hana Securities, Intron Biotechnology Co., Ltd., ValueSystem Investment Management, Mirae Asset Securities, T Investment, Muirwoods Ventures, KNOTUS, CKD Bio
- Series A, May 22, 2019, $4.2M — Shinhan Securities, NHN Investment, KB Securities

## Investors

- Shinhan Securities (https://capitalatlas.ai/funds/shinhan-securities) — Series A
- NHN Investment (https://capitalatlas.ai/funds/nhn-investment) — Series A
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series A
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series B
- Industrial Bank of Korea — Series B
- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series B
- LabGenomics. Co., Ltd. — Series B
- EuBiologics Co. Ltd. — Series B
- Hana Securities (https://capitalatlas.ai/funds/hana-securities) — Series B, Series C
- Intron Biotechnology Co., Ltd. — Series B
- ValueSystem Investment Management — Series B
- Mirae Asset Securities (https://capitalatlas.ai/funds/mirae-asset-securities) — Series B
- T Investment (https://capitalatlas.ai/funds/t-investment) — Series B
- Muirwoods Ventures (https://capitalatlas.ai/funds/muirwoods-ventures) — Series B
- KNOTUS — Series B
- CKD Bio — Series B, Series C